What does RAD-140 do to the brain? In the human brain, nothing that anyone has measured. The whole answer comes from cultured cells and from male rats, where the compound kept neurons alive under injury about as well as testosterone did, and whether the same holds in a person is unknown.
The compound shares its target with testosterone, the main androgen in men: the androgen receptor inside cells. In the cultured cells the protection ran through a known signalling cascade and blocked apoptosis, the orderly self-destruction a cell undergoes once damage signals pass a threshold; in the rats the compound switched on androgen-controlled genes in brain tissue and, after a nerve toxin, reduced the loss of neurons in the hippocampus (the memory region of the brain) while largely sparing prostate tissue, the androgen-dependent gland of the male reproductive tract. All of this is early animal work, and what the compound does in the human brain remains unknown.
RAD140 belongs to the selective androgen receptor modulators (SARMs), compounds developed to exert agonist effects in select androgen-responsive tissues with little androgen action in prostate tissue. The androgen receptor they bind is a nuclear receptor: testosterone switches it on, and the switched-on receptor regulates the transcription of androgen-controlled genes in tissues from skeletal muscle to brain tissue. Brain tissue expresses that receptor too, which is how a compound shaped for anabolic work in skeletal muscle came to be tested on neurons; the RAD 140 mechanism of action in those neurons starts from the same receptor.
This article sets out what the nerve-cell and rat experiments measured, how the protective effect worked in the cells, and where the evidence stops. Sport rules and UK legal status, covered on other pages of this site, stay outside it. The RAD-140 for sale to laboratories here is documented with batch and purity data.
Why researchers tested a SARM on the brain
The question behind the experiments was whether a SARM could protect neurons as endogenous androgens do, without the risk to prostate tissue that attends testosterone therapy. Testosterone declines in men during normal ageing, the decline raises the risk of dysfunction and disease in androgen-responsive organs, the brain included, and testosterone therapy, which might offset it, has the potential to increase the risk of developing prostate cancer or to accelerate its progression. The compounds termed selective androgen receptor modulators were developed against that limitation, lacking significant androgen action in the prostate while acting as agonists in selected androgen-responsive tissues, and their efficacy in brain tissue was largely unknown when this work began.
novel compounds termed “selective androgen receptor modulators” (SARMs) have been developed that lack significant androgen action in prostate but exert agonist effects in select androgen-responsive tissues. The efficacy of SARMs in brain is largely unknown.
Neuroprotection, in that literature, is the preservation of neurons under an insult that would otherwise kill them. Neurons are lost progressively in neurodegenerative disease, the group of disorders defined by that loss, above all in Alzheimer’s disease, which kills hippocampal and cortical neurons and takes memory with them, so a compound that holds neurons alive in a lesion model bears on that field. That is the line of enquiry the SARM RAD140 entered, and it has since become the starting point of the RAD-140 neuroprotective effects research.
Neither brain experiment took safety as an endpoint, and the published cases of RAD 140 liver injury stand in their own article.
What the nerve-cell experiments showed
Cultured neurons taken from the rat hippocampus and kept alive outside the animal, rather than studied in the intact brain, were exposed to apoptotic insults, triggers of apoptosis or programmed cell death, and RAD-140 was as effective as testosterone in reducing the cell death they induced. Since the comparison was drawn against testosterone itself, the RAD-140 neuroprotective effects measured here stand at roughly the level of the endogenous androgen and no higher.
A culture model establishes only that a compound can act on neurons under a defined insult, at a concentration the experimenter sets; in the intact animal the same compound must also be absorbed, distributed, metabolised and delivered to the tissue of interest, and none of those steps is tested in culture.
How RAD-140 protected the cells: the MAPK signal
The protection depended on MAPK signalling, a cascade of mitogen-activated protein kinases that carries survival signals through a cell, and two observations in the cultured neurons tie the effect to it. Testolone raised ERK phosphorylation, the addition of phosphate groups that switches on extracellular signal-regulated kinase, one link in that chain; and blocking the cascade with U0126 (an inhibitor of MAPK kinase) abolished the protection.
Switched on where the effect appeared and blocked where the effect vanished, the pathway reads as the route rather than a bystander. That detail matters to the brain question because it places the action in the neurons themselves rather than in something else in the culture.
[Figure 1. MAPK signalling behind RAD140 neuroprotection. In cultured rat hippocampal neurons the compound raised ERK (MAPK) signalling and lowered neuron death, and the MAPK blocker U0126 abolished that protection. Cells only, not animals or people; no cell counts given.]
What the rat brain study showed
The rats were gonadectomised adult males, gonadectomy being the surgical removal of the testes, so that they carried little testosterone of their own and any protection measured could be attributed to the compound administered. In those animals RAD-140 protected hippocampal neurons against cell death caused by systemic administration of the excitotoxin kainate, which kills neurons by overexciting them and whose lesion is a standard model of neuronal loss. Androgen action in peripheral tissues, tracked in the same experiments, proved tissue-specific and largely spared prostate tissue, the pattern that Tissue selectivity names: agonist action in some androgen-responsive tissues and little in others.
The authors called the result initial preclinical efficacy of a SARM in neuroprotective actions relevant to Alzheimer’s disease and related neurodegenerative diseases, and that wording sets the ceiling on what the RAD-140 neuroprotective animal studies can be said to show: before any human testing, an androgen receptor-targeted compound reduced hippocampal neuron loss in one rat lesion model while leaving prostate tissue largely untouched.
The two RAD140 neuroprotection experiments compared
Feature
Cultured hippocampal neurons
Gonadectomised adult male rats
Insult
Apoptotic insults
Systemic kainate, an excitotoxin
Comparison
Testosterone
Not stated in the abstract
Finding on neurons
As effective as testosterone in reducing cell death
Protected hippocampal neurons against kainate-induced death
Further evidence
ERK phosphorylation raised; protection blocked by U0126
Androgenic gene regulation activated in brain tissue
Prostate tissue
Not applicable
Largely spared
Does RAD140 cross the blood-brain barrier?
RAD140 appears to have crossed the blood-brain barrier in the rat experiments, the layer of cells lining brain blood vessels that keeps many circulating compounds out, but the evidence is indirect: the compound was shown to act within brain tissue. Genes under the control of the androgen receptor changed their expression there after administration, a change that requires RAD140 to have reached brain androgen receptors, and that activation of androgenic gene regulation, together with neuronal survival in the same animals, is the whole evidence of entry; how much of the compound got in is not quantified, because no measurement of its concentration in the brain appears in the published record.
What a longer mouse study found about overall health
The longer mouse study measured health span rather than any brain outcome, and at the dose tested the indices of overall health worsened. The investigators compared RAD140 at 5 mg/kg with a control solution in young and adult female mice over the period the table gives, subjected the dorsiflexors to repeated bouts of eccentric contractions, and measured torque before and after each bout.
From those measurements came adaptive potential and the increase in strength, as measures of efficacy in skeletal muscle, and frailty status and mortality risk, as measures of health span, both read from a frailty index, a tally of age-related health deficits. The arrangement addressed sarcopenia (the age-related loss of skeletal muscle mass and strength), a condition without any published long-term study of the compound.
The two sets of measures diverged, as the table below shows. Frailty status and mortality risk rose in both treated age groups relative to controls, torque after the recovery period did not differ between the groups, and adaptive potential fell in the young mice but not in the adult animals, so the age of the animal changed the outcome. Strength did not improve while the health-span indices worsened, and the authors concluded that at that dose the compound may be more detrimental than beneficial in delaying or preventing sarcopenia, a conclusion that runs opposite to the neuroprotection work and cannot be reconciled with it on the data, since the studies differ in species, sex, duration and the outcome measured.
Ten-week RAD140 mouse study by measure
Measure
What it stood for
Young female mice
Adult female mice
Frailty status and mortality risk
Health span
Rose against controls (p ≤ 0.042)
Rose against controls (p ≤ 0.042)
Adaptive potential
Efficacy in skeletal muscle
Fell (p = 0.040)
No difference (p = 0.688)
Torque after 2 to 3 weeks of recovery
Strength in the dorsiflexors
No difference between groups (p ≥ 0.135)
No difference between groups (p ≥ 0.135)
Study arms
Comparison tested
RAD140 at 5 mg/kg or control solution, 10 weeks
RAD140 at 5 mg/kg or control solution, 10 weeks
Where the brain evidence on RAD-140 stops
The brain evidence on RAD-140 stops at the species and models behind it. Neuroprotection was measured in cultured rat hippocampal neurons and in gonadectomised male rats lesioned with kainate, so the findings in the intact animal describe one insult in one sex of one species, and the health-span data, from female mice at a single dose over ten weeks, neither confirm nor contradict them, because the two studies measured different outcomes.
The TGA found under-dosing in SARM products sampled from one national market rather than in every preparation sold anywhere, and the LiverTox record on drug-induced liver injury covers selective androgen receptor modulators as a class, so it yields no rate for RAD-140. No human neurological outcome appears anywhere in that evidence: not in the cell and rat experiments, not in the mouse study, not in the product analyses or the liver monograph. That class record is set out under SARMs liver toxicity.
The neuroprotection experiments used a compound of known content, which products sold as RAD140 often are not, so what counts as legit RAD 140 is settled by analysis.
The rest of the UK SARMs in the shop carry the same batch data.
What each source can and cannot show
Source
Model or scope
What it measured
Where it stops
Neuroprotection study, 2014
Cultured rat hippocampal neurons; gonadectomised male rats
Neuron survival after apoptotic insults and kainate
One lesion model, one sex, one species; animal only
RAD140 is generally held not to have been tested in the human brain: the neuroprotection findings come from cultured neurons and from rodent models of excitotoxic injury, no human study is described as having measured a brain-related outcome, and the human RAD 140 study was a small early-phase clinical trial in breast cancer under the name vosilasarm, directed at safety, tolerability and pharmacokinetics rather than at any neurological endpoint, so whether the animal findings would carry over to humans is unknown.
Does RAD140 affect memory, mood or cognition?
RAD140 is generally held to have no established effect on memory, mood or cognition, because the research bearing on them is preclinical: the compound reduced neuronal death in cultured hippocampal neurons and in the rodent hippocampus after excitotoxic injury, through an effect that depends on the androgen receptor, but neuronal survival in such a model is not an improvement in memory performance, and that work did not focus on behavioural endpoints.
The case for an effect on mood rests on a different line of reasoning. Androgen signalling is generally held to influence mood, and SARMs are described as suppressing endogenous testosterone, so a link between SARMs, mood and the brain is plausible in principle and uncharacterised in fact; no controlled human study of RAD 140 has measured a cognitive or mood endpoint.
Has the neuroprotection finding been replicated by other labs?
The neuroprotection finding is generally held to have been replicated only to a limited extent by independent laboratories, since it comes mainly from one research group’s preclinical work, and the RAD-140 brain finding is described as an early, single-source preclinical result, unconfirmed in humans, whose record consists of:
that group’s cultured hippocampal neurons;
its rodent excitotoxic lesion model in gonadectomised animals;
the reduced neuronal death it reported through an androgen receptor-dependent signalling pathway;
later papers that mostly cite that original result rather than repeat its experiments.
Separate cell and animal studies do support the wider proposition that androgens and SARMs can protect neurons, in those accounts, though none of them shows what RAD-140 does to the brain in humans.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In cultured rat hippocampal neurons, how did RAD140 compare with testosterone against apoptotic insults?
It reduced cell death about as well as testosterone did ✓
It reduced cell death several times more than testosterone
It reduced cell death only alongside added testosterone
It reduced cell death about half as well as testosterone
The study found RAD140 as effective as testosterone in reducing cell death, so its protection sat at roughly the level of the natural androgen and no higher.
Which observation tied the protection in cultured neurons to MAPK signalling?
Blocking the cascade with U0126 left the protection intact
Blocking the cascade with U0126 abolished the protection ✓
The protected neurons showed lower ERK phosphorylation
The cascade stayed silent while the neurons survived
RAD140 raised ERK phosphorylation, and blocking the cascade with the inhibitor U0126 made the protection disappear, which links the effect to that pathway.
What is the evidence that RAD140 reached brain tissue in the rat experiments?
Its concentration was measured directly in brain tissue
Imaging traced the compound across the blood-brain barrier
Androgen-controlled genes changed expression in brain tissue ✓
Its level in cerebrospinal fluid matched its level in the blood
The evidence is indirect: androgen-controlled genes were switched on in brain tissue, but no concentration of RAD140 in the brain was ever measured.
In the ten-week study in young and adult female mice, what happened to frailty status and mortality risk?
They fell against controls in both age groups as strength rose
They rose in the young mice only, not in the adults
They did not differ from those of the control mice
They rose against controls in both young and adult mice ✓
Frailty status and mortality risk rose in both treated age groups while strength did not improve, so the authors judged the compound more detrimental than beneficial there.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Hélène N. Daou is a BHF postdoctoral research fellow in the School of Biomedical Sciences at the University of Leeds. Hélène specialises in PPAR-delta pharmacology and in preclinical and animal models.
The first RAD 140 study tested the compound in 22 postmenopausal women with metastatic breast cancer, setting 100 mg daily as the highest tolerated dose.
RAD 140 before and after accounts report rises in body weight and strength, but no study has measured how much is muscle or what remains after exposure.
MK-677 Reddit accounts describe increased appetite and deeper sleep early on, while trials recorded more fat-free mass and IGF-1 but no rise in strength.
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
What does RAD-140 do to the brain? Neuron and rat studies
By Laura Walker, PhD · Reviewed by Hélène N. Daou, PhD
Published · Updated · 13 min read
What RAD-140 does to the brain: the short version
What does RAD-140 do to the brain? In the human brain, nothing that anyone has measured. The whole answer comes from cultured cells and from male rats, where the compound kept neurons alive under injury about as well as testosterone did, and whether the same holds in a person is unknown.
The compound shares its target with testosterone, the main androgen in men: the androgen receptor inside cells. In the cultured cells the protection ran through a known signalling cascade and blocked apoptosis, the orderly self-destruction a cell undergoes once damage signals pass a threshold; in the rats the compound switched on androgen-controlled genes in brain tissue and, after a nerve toxin, reduced the loss of neurons in the hippocampus (the memory region of the brain) while largely sparing prostate tissue, the androgen-dependent gland of the male reproductive tract. All of this is early animal work, and what the compound does in the human brain remains unknown.
RAD140 belongs to the selective androgen receptor modulators (SARMs), compounds developed to exert agonist effects in select androgen-responsive tissues with little androgen action in prostate tissue. The androgen receptor they bind is a nuclear receptor: testosterone switches it on, and the switched-on receptor regulates the transcription of androgen-controlled genes in tissues from skeletal muscle to brain tissue. Brain tissue expresses that receptor too, which is how a compound shaped for anabolic work in skeletal muscle came to be tested on neurons; the RAD 140 mechanism of action in those neurons starts from the same receptor.
This article sets out what the nerve-cell and rat experiments measured, how the protective effect worked in the cells, and where the evidence stops. Sport rules and UK legal status, covered on other pages of this site, stay outside it. The RAD-140 for sale to laboratories here is documented with batch and purity data.
Why researchers tested a SARM on the brain
The question behind the experiments was whether a SARM could protect neurons as endogenous androgens do, without the risk to prostate tissue that attends testosterone therapy. Testosterone declines in men during normal ageing, the decline raises the risk of dysfunction and disease in androgen-responsive organs, the brain included, and testosterone therapy, which might offset it, has the potential to increase the risk of developing prostate cancer or to accelerate its progression. The compounds termed selective androgen receptor modulators were developed against that limitation, lacking significant androgen action in the prostate while acting as agonists in selected androgen-responsive tissues, and their efficacy in brain tissue was largely unknown when this work began.
Neuroprotection, in that literature, is the preservation of neurons under an insult that would otherwise kill them. Neurons are lost progressively in neurodegenerative disease, the group of disorders defined by that loss, above all in Alzheimer’s disease, which kills hippocampal and cortical neurons and takes memory with them, so a compound that holds neurons alive in a lesion model bears on that field. That is the line of enquiry the SARM RAD140 entered, and it has since become the starting point of the RAD-140 neuroprotective effects research.
Neither brain experiment took safety as an endpoint, and the published cases of RAD 140 liver injury stand in their own article.
What the nerve-cell experiments showed
Cultured neurons taken from the rat hippocampus and kept alive outside the animal, rather than studied in the intact brain, were exposed to apoptotic insults, triggers of apoptosis or programmed cell death, and RAD-140 was as effective as testosterone in reducing the cell death they induced. Since the comparison was drawn against testosterone itself, the RAD-140 neuroprotective effects measured here stand at roughly the level of the endogenous androgen and no higher.
A culture model establishes only that a compound can act on neurons under a defined insult, at a concentration the experimenter sets; in the intact animal the same compound must also be absorbed, distributed, metabolised and delivered to the tissue of interest, and none of those steps is tested in culture.
How RAD-140 protected the cells: the MAPK signal
The protection depended on MAPK signalling, a cascade of mitogen-activated protein kinases that carries survival signals through a cell, and two observations in the cultured neurons tie the effect to it. Testolone raised ERK phosphorylation, the addition of phosphate groups that switches on extracellular signal-regulated kinase, one link in that chain; and blocking the cascade with U0126 (an inhibitor of MAPK kinase) abolished the protection.
Switched on where the effect appeared and blocked where the effect vanished, the pathway reads as the route rather than a bystander. That detail matters to the brain question because it places the action in the neurons themselves rather than in something else in the culture.
What the rat brain study showed
The rats were gonadectomised adult males, gonadectomy being the surgical removal of the testes, so that they carried little testosterone of their own and any protection measured could be attributed to the compound administered. In those animals RAD-140 protected hippocampal neurons against cell death caused by systemic administration of the excitotoxin kainate, which kills neurons by overexciting them and whose lesion is a standard model of neuronal loss. Androgen action in peripheral tissues, tracked in the same experiments, proved tissue-specific and largely spared prostate tissue, the pattern that Tissue selectivity names: agonist action in some androgen-responsive tissues and little in others.
The authors called the result initial preclinical efficacy of a SARM in neuroprotective actions relevant to Alzheimer’s disease and related neurodegenerative diseases, and that wording sets the ceiling on what the RAD-140 neuroprotective animal studies can be said to show: before any human testing, an androgen receptor-targeted compound reduced hippocampal neuron loss in one rat lesion model while leaving prostate tissue largely untouched.
The two RAD140 neuroprotection experiments compared
Does RAD140 cross the blood-brain barrier?
RAD140 appears to have crossed the blood-brain barrier in the rat experiments, the layer of cells lining brain blood vessels that keeps many circulating compounds out, but the evidence is indirect: the compound was shown to act within brain tissue. Genes under the control of the androgen receptor changed their expression there after administration, a change that requires RAD140 to have reached brain androgen receptors, and that activation of androgenic gene regulation, together with neuronal survival in the same animals, is the whole evidence of entry; how much of the compound got in is not quantified, because no measurement of its concentration in the brain appears in the published record.
What a longer mouse study found about overall health
The longer mouse study measured health span rather than any brain outcome, and at the dose tested the indices of overall health worsened. The investigators compared RAD140 at 5 mg/kg with a control solution in young and adult female mice over the period the table gives, subjected the dorsiflexors to repeated bouts of eccentric contractions, and measured torque before and after each bout.
From those measurements came adaptive potential and the increase in strength, as measures of efficacy in skeletal muscle, and frailty status and mortality risk, as measures of health span, both read from a frailty index, a tally of age-related health deficits. The arrangement addressed sarcopenia (the age-related loss of skeletal muscle mass and strength), a condition without any published long-term study of the compound.
The two sets of measures diverged, as the table below shows. Frailty status and mortality risk rose in both treated age groups relative to controls, torque after the recovery period did not differ between the groups, and adaptive potential fell in the young mice but not in the adult animals, so the age of the animal changed the outcome. Strength did not improve while the health-span indices worsened, and the authors concluded that at that dose the compound may be more detrimental than beneficial in delaying or preventing sarcopenia, a conclusion that runs opposite to the neuroprotection work and cannot be reconciled with it on the data, since the studies differ in species, sex, duration and the outcome measured.
Ten-week RAD140 mouse study by measure
Where the brain evidence on RAD-140 stops
The brain evidence on RAD-140 stops at the species and models behind it. Neuroprotection was measured in cultured rat hippocampal neurons and in gonadectomised male rats lesioned with kainate, so the findings in the intact animal describe one insult in one sex of one species, and the health-span data, from female mice at a single dose over ten weeks, neither confirm nor contradict them, because the two studies measured different outcomes.
The TGA found under-dosing in SARM products sampled from one national market rather than in every preparation sold anywhere, and the LiverTox record on drug-induced liver injury covers selective androgen receptor modulators as a class, so it yields no rate for RAD-140. No human neurological outcome appears anywhere in that evidence: not in the cell and rat experiments, not in the mouse study, not in the product analyses or the liver monograph. That class record is set out under SARMs liver toxicity.
The neuroprotection experiments used a compound of known content, which products sold as RAD140 often are not, so what counts as legit RAD 140 is settled by analysis.
The rest of the UK SARMs in the shop carry the same batch data.
What each source can and cannot show
Has RAD140 been tested in the brain in humans?
RAD140 is generally held not to have been tested in the human brain: the neuroprotection findings come from cultured neurons and from rodent models of excitotoxic injury, no human study is described as having measured a brain-related outcome, and the human RAD 140 study was a small early-phase clinical trial in breast cancer under the name vosilasarm, directed at safety, tolerability and pharmacokinetics rather than at any neurological endpoint, so whether the animal findings would carry over to humans is unknown.
Does RAD140 affect memory, mood or cognition?
RAD140 is generally held to have no established effect on memory, mood or cognition, because the research bearing on them is preclinical: the compound reduced neuronal death in cultured hippocampal neurons and in the rodent hippocampus after excitotoxic injury, through an effect that depends on the androgen receptor, but neuronal survival in such a model is not an improvement in memory performance, and that work did not focus on behavioural endpoints.
The case for an effect on mood rests on a different line of reasoning. Androgen signalling is generally held to influence mood, and SARMs are described as suppressing endogenous testosterone, so a link between SARMs, mood and the brain is plausible in principle and uncharacterised in fact; no controlled human study of RAD 140 has measured a cognitive or mood endpoint.
Has the neuroprotection finding been replicated by other labs?
The neuroprotection finding is generally held to have been replicated only to a limited extent by independent laboratories, since it comes mainly from one research group’s preclinical work, and the RAD-140 brain finding is described as an early, single-source preclinical result, unconfirmed in humans, whose record consists of:
Separate cell and animal studies do support the wider proposition that androgens and SARMs can protect neurons, in those accounts, though none of them shows what RAD-140 does to the brain in humans.
Check what you remember
4 questions on this article; the right answer is marked.
The study found RAD140 as effective as testosterone in reducing cell death, so its protection sat at roughly the level of the natural androgen and no higher.
RAD140 raised ERK phosphorylation, and blocking the cascade with the inhibitor U0126 made the protection disappear, which links the effect to that pathway.
The evidence is indirect: androgen-controlled genes were switched on in brain tissue, but no concentration of RAD140 in the brain was ever measured.
Frailty status and mortality risk rose in both treated age groups while strength did not improve, so the authors judged the compound more detrimental than beneficial there.
Laura Walker, PhD · Newcastle University
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Hélène N. Daou, PhD · University of Leeds · Last reviewed
BHF Postdoctoral Research Fellow
Hélène N. Daou is a BHF postdoctoral research fellow in the School of Biomedical Sciences at the University of Leeds. Hélène specialises in PPAR-delta pharmacology and in preclinical and animal models.
Related Posts
RAD 140 study: what the breast-cancer trials found
The first RAD 140 study tested the compound in 22 postmenopausal women with metastatic breast cancer, setting 100 mg daily as the highest tolerated dose.
RAD 140 before and after: muscle, strength and what lasts
RAD 140 before and after accounts report rises in body weight and strength, but no study has measured how much is muscle or what remains after exposure.
MK-677 Reddit: discussions weighed against the trials
MK-677 Reddit accounts describe increased appetite and deeper sleep early on, while trials recorded more fat-free mass and IGF-1 but no rise in strength.
Ostarine for cutting: lean mass and fat loss in the trials
ostarine for cutting is untested in lean adults, but in a semaglutide weight-loss trial enobosarm cut lean-mass loss by 71% and raised fat loss by 27%.